ClinicalTrials.gg
CompletedNCT05420961Updated Oct 26, 2024Results posted

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

A Phase 3 interventional study of V116 and PCV15 in Pneumonia, Pneumococcal, sponsored by Merck Sharp & Dohme LLC. Completed at 51 sites in 9 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
717
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Pneumonia, Pneumococcal with a site in United States — none open to participants now, none under way, none of them phase 3. Pneumonia, Pneumococcal · United States.

Enrollment
4th of 11
717 · median 431
Started
2022
with 2 others
Phase 3
4 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
4 of 12
Merck Sharp & Dohme LLC

Among the 12 studies in Pneumonia, Pneumococcal with a site in United States, this one is the 4th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2022, is one of 4 in phase 3, and was the 9th registered.

Pneumonia, Pneumococcal

44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.

Browse Pneumonia, Pneumococcal studies →

Open to participants now

None of the 12 studies in Pneumonia, Pneumococcal with a site in United States is open now. The open studies under Pneumonia, Pneumococcal, anywhere →

Who these studies take

Of the 1 Pneumonia, Pneumococcal study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Pneumonia, Pneumococcal with a site in United States as a file.
02

Study summary

This a study of V116 in adults ≥50 years of age who previously received a pneumococcal vaccination ≥1 year before enrollment. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116.

Read the detailed description

Participants will be randomized to 1 of 3 cohorts depending upon prior vaccinations. Prior vaccinations by cohort include: PPSV23 (pneumococcal vaccine, polyvalent [23-valent], PNEUMOVAX™23) for Cohort 1; PCV13 (pneumococcal 13-valent conjugate vaccine; PREVNAR 13™) for Cohort 2; PCV15 (pneumococcal 15-valent conjugate vaccine; VAXNEUVANCE™), PCV20 (pneumococcal 20-valent conjugate vaccine; PREVNAR 20™), PCV13+PPSV23, PCV15+PPSV23, or PPSV23+PCV13 for Cohort 3.

03

Conditions studied

  • Pneumonia, Pneumococcal
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion criteria

Inclusion Criteria:

  • Has received pneumococcal vaccine >= 1 year before enrollment (PCV13, PCV15, PCV20, PPSV23, PCV13+PPSV23, PPSV23+PCV13, or PCV15+PPSV23).

Exclusion criteria

Exclusion Criteria:

  • Has a history of invasive pneumococcal disease (IPD).
  • Has a known to any component of V116, PCV15, PCV20, or PPSV23, including diphtheria toxoid.
  • Has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented (HIV) infection, functional or anatomic asplenia, or history of disease.
  • Has a coagulation disorder contraindicating intramuscular vaccination.
  • Has a known that is progressing or has required active treatment.
  • Has received PPSV23 followed by either PCV15 or PCV20.
  • Received systemic (prednisone equivalent of ≥20 mg/day).
  • Is currently receiving therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
  • Has received any non- ≤14 days before receipt of study vaccine or is scheduled to receive any non-live vaccine ≤30 days after receipt of any study vaccine.
  • Has received any live virus vaccine ≤30 days before receipt of study vaccine or is scheduled to receive any live virus vaccine ≤30 days after receipt of study vaccine.
  • Has received a blood transfusion or blood products, including immunoglobulin ≤6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product until the Day 30 post-vaccination blood draw is complete.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
717 participants (actual)

Study arms

  • Experimental
    Cohort 1: V116

    Participants will receive a single 0.5 mL intramuscular (IM) injection of V116 on Day 1. Participants in this arm received PPSV23 prior to the enrollment.

    Biological: V116

  • Active comparator
    Cohort 1: PCV15

    Participants will receive a single 0.5 mL IM injection of PCV15 on Day 1. Participants in this arm received PPSV23 prior to the enrollment.

    Biological: PCV15

  • Experimental
    Cohort 2: V116

    Participants will receive a single 0.5 mL IM injection of V116 on Day 1. Participants in this arm received PCV13 prior to the enrollment.

    Biological: V116

  • Active comparator
    Cohort 2: PPSV23

    Participants will receive a single 0.5 mL IM injection of PPSV23 on Day 1. Participants in this arm received PCV13 prior to the enrollment.

    Biological: PPSV23

  • Experimental
    Cohort 3: V116

    Participants will receive a single 0.5 mL IM injection of V116 on Day 1. Participants in this arm received PCV15, PCV20, PCV13+PPSV23, PCV15+PPSV23, or PPSV23+PCV13 prior to the enrollment.

    Biological: V116

Interventions

  • BiologicalV116

    Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

    Also known as: Pneumococcal 21-valent Conjugate Vaccine

  • BiologicalPCV15

    Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile suspension

    Also known as: VAXNEUVANCE™

  • BiologicalPPSV23

    Drug page: 23-valent pneumococcal capsular polysaccharide vaccine

    Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

    Also known as: PNEUMOVAX™23

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Solicited Injection-site Adverse Events (AEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following any injection with either V116, PCV15, or PPSV23 the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were erythema, pain, and swelling.

    Time frame: Up to 5 days post-vaccination

  2. Percentage of Participants With Solicited Systemic AEs

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following any of the injections with either V116, PCV15, or PPSV23, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were fatigue, headache, myalgia, and pyrexia.

    Time frame: Up to 5 days post-vaccination

  3. Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)

    A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. The percentage of participants with one or more SAE that were assessed by the investigator to be at least possibly related to the study vaccination are presented.

    Time frame: Up to ~180 days

  4. Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA)

    OPA for the serotypes contained in V116 were determined using a multiplex opsonophagocytic assay (MOPA). GMT is defined as geometric mean titer (1/dil). Serotype-specific OPA GMTs with 95% confidence intervals are presented.

    Time frame: 30 Days post-vaccination

Secondary outcomes

  1. Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG)

    The geometric mean concentration (GMC) of serotype-specific immunoglobulin G (IgG) for the serotypes contained in V116 was determined using a pneumococcal electrochemiluminescence (PnECL) assay. Serotype-specific pneumococcal IgG GMCs with 95% confidence intervals are presented.

    Time frame: 30 Days post-vaccination

  2. Geometric Mean Fold Rise in Serotype-specific Opsonophagocytic Activity (OPA)

    Activity for the serotypes contained in V116 was determined using a multiplex opsonophagocytic assay (MOPA). Geometric mean fold rise (GMFR) is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline. The GMFRs in OPA responses from baseline to 30 days post-vaccination with 95% confidence intervals are presented.

    Time frame: Day 1 (Baseline) and 30 days post-vaccination

  3. Percentage of Participants Who Achieve a ≥4-fold Increase in Serotype-specific OPA Responses

    Activity for the serotypes contained in V116 was determined using a MOPA. The percentage of participants with a ≥4-fold rise from baseline to at 30 days post-vaccination for OPA responses with 95% confidence intervals are presented.

    Time frame: Day 1 (Baseline) and 30 days post-vaccination

  4. Geometric Mean Fold Rise of Serotype-specific IgG

    Activity for the serotypes contained in V116 was determined using a PnECL assay. Geometric mean fold rise (GMFR) is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline. The GMFRs IgG responses from baseline to 30 days post-vaccination with 95% confidence intervals are presented.

    Time frame: Day 1 (Baseline) and 30 days post-vaccination

  5. Percentage of Participants Who Achieve a ≥4-fold Increase in Serotype-specific IgG Response

    Activity for the serotypes contained in V116 was determined using a PnECL assay. The percentage of participants with a ≥4-fold rise from baseline to at 30 days post-vaccination for IgG responses with 95% confidence intervals are presented.

    Time frame: Day 1 (Baseline) and 30 days post-vaccination

07

Results

Posted May 1, 2024

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116
Started23111917685106
Day 1 - vaccinated with v11622911740105
Day 1 - vaccinated with pcv150117000
Day 1 - vaccinated with ppsv23010850
Completed22911817385105
Not completed21301
Withdrew: Withdrawal by subject21100
Withdrew: Lost to follow-up00100
Withdrew: Randomized by mistake without study treatment00101

Outcome measures

PrimaryPercentage of Participants With Solicited Injection-site Adverse Events (AEs)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following any injection with either V116, PCV15, or PPSV23 the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were erythema, pain, and swelling.

Time frame:
Up to 5 days post-vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With Solicited Injection-site Adverse Events (AEs)
Percentage of ParticipantsCohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116
Injection site erythema7.47.77.59.47.6
Injection site pain35.743.641.447.143.8
Injection site swelling8.38.54.616.510.5
PrimaryPercentage of Participants With Solicited Systemic AEs

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following any of the injections with either V116, PCV15, or PPSV23, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were fatigue, headache, myalgia, and pyrexia.

Time frame:
Up to 5 days post-vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With Solicited Systemic AEs
Percentage of ParticipantsCohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116
Fatigue14.317.119.012.921.9
Headache7.09.410.311.88.6
Myalgia7.42.69.89.48.6
Pyrexia1.72.62.91.20.0
PrimaryPercentage of Participants With Vaccine-related Serious Adverse Events (SAEs)

A serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. The percentage of participants with one or more SAE that were assessed by the investigator to be at least possibly related to the study vaccination are presented.

Time frame:
Up to ~180 days
Reported as:
Number · Percentage of Participants
Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)
Percentage of ParticipantsCohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116
Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)0.40.00.00.00.0
PrimaryGeometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA)

OPA for the serotypes contained in V116 were determined using a multiplex opsonophagocytic assay (MOPA). GMT is defined as geometric mean titer (1/dil). Serotype-specific OPA GMTs with 95% confidence intervals are presented.

Time frame:
30 Days post-vaccination
Reported as:
Geometric mean · Titers
Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA)
TitersCohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116
Serotype 3262.1 (224.0 to 306.8)226.3 (182.0 to 281.4)391.1 (332.8 to 459.6)583.1 (453.5 to 749.6)318.3 (250.0 to 405.3)
Serotype 6A1653.5 (1347.2 to 2029.4)2076.1 (1571.4 to 2742.8)3624.0 (3099.2 to 4237.7)1812.3 (1226.6 to 2677.6)2097.3 (1693.4 to 2597.6)
Serotype 7F2184.4 (1891.4 to 2522.8)1750.3 (1404.7 to 2181.0)3129.8 (2609.9 to 3753.3)4057.0 (3211.2 to 5125.6)2051.3 (1630.2 to 2581.0)
Serotype 19A1513.8 (1318.4 to 1738.1)2022.9 (1634.1 to 2504.3)2528.9 (2201.7 to 2904.9)3241.5 (2646.0 to 3971.0)1533.8 (1272.4 to 1848.9)
Serotype 22F1983.8 (1698.3 to 2317.4)1595.6 (1227.1 to 2074.6)4389.2 (3541.1 to 5440.3)2524.0 (1834.5 to 3472.5)1913.5 (1453.5 to 2519.0)
Serotype 33F4311.9 (3625.1 to 5128.9)3397.2 (2665.3 to 4330.0)8162.9 (6407.2 to 10399.7)8761.9 (6157.4 to 12468.1)4654.3 (3532.1 to 6133.1)
Serotype 81273.0 (1115.1 to 1453.3)345.8 (250.5 to 477.5)2320.1 (1987.3 to 2708.7)2723.2 (2197.4 to 3374.8)1486.8 (1230.5 to 1796.6)
Serotype 9N3805.1 (3324.0 to 4356.0)2176.5 (1809.6 to 2617.9)7214.4 (6062.9 to 8584.6)6482.5 (4908.9 to 8560.7)4054.5 (3389.4 to 4850.2)
Serotype 10A1986.2 (1637.7 to 2408.9)467.5 (337.0 to 648.5)3976.8 (3360.7 to 4705.8)1797.6 (1136.2 to 2843.9)2564.0 (1959.1 to 3355.6)
Serotype 11A1998.5 (1696.9 to 2353.8)335.6 (228.9 to 491.8)2846.6 (2411.0 to 3360.8)1736.6 (1367.1 to 2206.1)2373.0 (1905.4 to 2955.4)
Serotype 12F981.8 (782.4 to 1232.1)80.5 (54.0 to 120.1)2252.6 (2120.5 to 3072.9)1402.5 (912.2 to 2156.4)1235.3 (948.3 to 1609.2)
Serotype 15A4184.9 (3548.3 to 4935.6)877.2 (616.2 to 1248.7)6185.2 (5179.3 to 7386.6)1668.2 (1234.4 to 2254.5)4328.6 (3378.7 to 5545.7)
Serotype 15C2307.8 (1878.4 to 2835.4)539.6 (371.1 to 784.6)4334.4 (3563.8 to 5271.5)1470.4 (978.6 to 2209.3)2191.9 (1573.2 to 3053.9)
Serotype 16F3060.5 (2633.8 to 3556.3)392.3 (301.3 to 510.8)4626.5 (3861.8 to 5542.6)832.8 (604.3 to 1147.6)2477.0 (1887.2 to 3251.2)
Serotype 17F3599.8 (3134.5 to 4134.3)939.6 (693.7 to 1272.6)5963.8 (5036.6 to 7061.7)4367.3 (3372.5 to 5655.7)3836.7 (3063.4 to 4805.1)
Serotype 20A2847.4 (2433.3 to 3331.8)1058.9 (829.9 to 1351.1)6005.5 (4919.8 to 7330.8)3393.9 (2536.9 to 4540.5)2433.4 (1880.5 to 3148.9)
Serotype 23A2363.9 (1857.4 to 3008.5)310.2 (202.1 to 476.0)4253.4 (3417.6 to 5293.5)433.6 (247.5 to 759.5)3967.2 (2764.8 to 5692.7)
Serotype 23B673.2 (517.1 to 876.4)153.0 (98.7 to 237.1)1530.7 (1196.5 to 1958.3)203.9 (127.6 to 325.6)844.0 (608.2 to 1171.4)
Serotype 24F1822.6 (1411.6 to 2353.3)106.6 (69.7 to 162.9)2746.1 (2257.9 to 3339.9)48.5 (28.6 to 82.1)2041.5 (1500.8 to 2777.1)
Serotype 313018.4 (2473.6 to 3683.3)113.2 (74.5 to 172.1)4413.5 (3530.2 to 5517.7)171.8 (99.9 to 295.6)3285.5 (2485.0 to 4343.8)
Serotype 35B6703.1 (5732.7 to 7837.8)1019.1 (739.9 to 1403.7)8143.5 (6761.4 to 9808.1)1527.7 (1169.5 to 1995.5)5836.8 (4693.6 to 7258.6)
SecondaryGeometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG)

The geometric mean concentration (GMC) of serotype-specific immunoglobulin G (IgG) for the serotypes contained in V116 was determined using a pneumococcal electrochemiluminescence (PnECL) assay. Serotype-specific pneumococcal IgG GMCs with 95% confidence intervals are presented.

Time frame:
30 Days post-vaccination
Reported as:
Geometric mean · μg/mL
Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG)
μg/mLCohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116
Serotype 30.87 (0.77 to 0.99)0.80 (0.65 to 0.97)0.89 (0.77 to 1.03)1.58 (1.25 to 2.00)0.85 (0.70 to 1.03)
Serotype 6A4.69 (3.72 to 5.90)7.69 (5.60 to 10.57)7.81 (6.30 to 9.68)5.24 (3.62 to 7.56)5.48 (4.27 to 7.03)
Serotype 7F5.71 (4.89 to 6.68)6.45 (5.08 to 8.19)5.65 (4.75 to 6.73)8.34 (6.57 to 10.59)5.07 (4.12 to 6.23)
Serotype 19A8.54 (7.33 to 9.95)11.97 (9.40 to 15.24)9.12 (7.70 to 10.81)12.41 (9.57 to 16.11)8.06 (6.50 to 9.98)
Serotype 22F4.41 (3.69 to 5.28)4.33 (3.37 to 5.56)5.38 (4.34 to 6.66)2.87 (2.12 to 3.87)3.08 (2.36 to 4.01)
Serotype 33F13.36 (11.22 to 15.91)12.72 (10.37 to 15.61)15.04 (12.31 to 18.37)13.92 (10.23 to 18.94)9.66 (7.53 to 12.40)
Serotype 89.58 (8.21 to 11.17)3.56 (2.74 to 4.62)11.29 (9.28 to 13.73)14.47 (10.86 to 19.27)7.48 (5.87 to 9.53)
Serotype 9N7.06 (5.92 to 8.43)3.59 (2.83 to 4.55)8.48 (6.89 to 10.44)7.32 (5.47 to 9.78)4.15 (3.23 to 5.34)
Serotype 10A9.86 (7.99 to 12.18)2.77 (2.12 to 3.63)18.21 (14.30 to 23.18)7.29 (4.94 to 10.74)10.03 (7.21 to 13.98)
Serotype 11A7.16 (6.09 to 8.42)2.06 (1.65 to 2.58)9.13 (7.44 to 11.22)3.95 (2.98 to 5.23)4.78 (3.79 to 6.03)
Serotype 12F1.46 (1.18 to 1.81)0.41 (0.30 to 0.55)1.91 (1.44 to 2.53)1.01 (0.65 to 1.56)0.96 (0.70 to 1.31)
Serotype 15A16.35 (13.45 to 19.88)1.56 (1.19 to 2.05)20.24 (15.92 to 25.75)2.15 (1.52 to 3.03)11.16 (7.91 to 15.75)
Serotype 15C11.08 (9.01 to 13.62)3.25 (2.37 to 4.45)16.67 (12.78 to 21.76)4.31 (2.91 to 6.38)6.51 (4.72 to 8.99)
Serotype 16F4.69 (3.75 to 5.87)0.37 (0.28 to 0.48)4.04 (3.19 to 5.10)0.30 (0.22 to 0.41)2.46 (1.78 to 3.41)
Serotype 17F13.20 (11.18 to 15.58)2.68 (2.08 to 3.46)14.96 (12.37 to 18.08)7.23 (5.26 to 9.92)9.92 (7.86 to 12.53)
Serotype 20A14.83 (12.37 to 17.77)4.93 (3.83 to 6.36)22.21 (17.77 to 27.75)10.73 (7.48 to 15.41)12.16 (8.99 to 16.46)
Serotype 23A5.38 (4.19 to 6.90)0.75 (0.55 to 1.02)6.03 (4.55 to 7.99)0.62 (0.43 to 0.90)4.25 (2.88 to 6.26)
Serotype 23B6.66 (5.53 to 8.03)2.61 (1.96 to 3.48)6.00 (4.91 to 7.33)2.31 (1.75 to 3.06)5.05 (3.90 to 6.54)
Serotype 24F10.05 (7.59 to 13.32)0.49 (0.39 to 0.61)7.48 (5.45 to 10.46)0.31 (0.23 to 0.42)6.12 (3.84 to 9.75)
Serotype 314.48 (3.66 to 5.48)0.37 (0.30 to 0.47)3.58 (2.87 to 4.46)0.32 (0.24 to 0.44)3.66 (2.64 to 5.08)
Serotype 35B26.31 (21.60 to 32.04)1.45 (1.18 to 1.78)24.55 (20.09 to 30.01)1.45 (1.17 to 1.80)18.15 (13.61 to 24.21)
SecondaryGeometric Mean Fold Rise in Serotype-specific Opsonophagocytic Activity (OPA)

Activity for the serotypes contained in V116 was determined using a multiplex opsonophagocytic assay (MOPA). Geometric mean fold rise (GMFR) is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline. The GMFRs in OPA responses from baseline to 30 days post-vaccination with 95% confidence intervals are presented.

Time frame:
Day 1 (Baseline) and 30 days post-vaccination
Reported as:
Geometric mean · Ratio
Geometric Mean Fold Rise in Serotype-specific Opsonophagocytic Activity (OPA)
RatioCohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116
Serotype 34.4 (3.7 to 5.3)4.0 (3.1 to 5.3)6.2 (5.0 to 7.6)7.5 (5.3 to 10.5)5.0 (3.6 to 7.0)
Serotype 6A6.2 (5.0 to 7.7)7.1 (4.9 to 10.3)4.2 (3.3 to 5.3)1.8 (1.4 to 2.4)5.5 (4.1 to 7.4)
Serotype 7F4.1 (3.3 to 5.1)3.9 (2.8 to 5.4)4.6 (3.6 to 5.9)4.2 (3.1 to 5.8)3.9 (2.9 to 5.3)
Serotype 19A2.4 (2.0 to 2.8)3.3 (2.5 to 4.4)2.8 (2.3 to 3.3)3.6 (2.7 to 4.7)2.5 (1.8 to 3.3)
Serotype 22F7.0 (5.5 to 9.0)7.1 (4.8 to 10.6)26.3 (17.7 to 39.2)14.8 (8.7 to 25.1)7.5 (4.9 to 11.4)
Serotype 33F2.2 (1.8 to 2.6)1.7 (1.3 to 2.4)6.3 (4.8 to 8.4)9.2 (5.6 to 15.3)2.7 (2.0 to 3.7)
Serotype 82.8 (2.4 to 3.4)0.9 (0.7 to 1.0)16.6 (12.2 to 22.7)18.6 (11.9 to 29.1)3.8 (2.7 to 5.3)
Serotype 9N2.3 (2.0 to 2.7)1.4 (1.1 to 1.7)5.9 (4.7 to 7.4)6.8 (4.7 to 9.8)3.5 (2.7 to 4.5)
Serotype 10A4.3 (3.5 to 5.4)1.0 (0.9 to 1.2)17.1 (12.7 to 23.0)11.8 (7.5 to 18.6)4.7 (3.4 to 6.5)
Serotype 11A6.5 (5.2 to 8.2)1.2 (0.9 to 1.7)21.0 (14.6 to 30.4)9.2 (5.9 to 14.4)9.5 (6.2 to 14.4)
Serotype 12F11.8 (9.0 to 15.4)1.1 (1.0 to 1.3)82.2 (62.9 to 107.4)41.9 (26.1 to 67.2)13.7 (9.0 to 20.8)
Serotype 15A5.6 (4.3 to 7.4)1.2 (0.9 to 1.5)9.0 (6.8 to 11.8)3.0 (2.0 to 4.5)7.2 (4.6 to 11.2)
Serotype 15C8.5 (6.7 to 10.9)1.3 (1.0 to 1.7)30.6 (22.5 to 41.5)12.7 (8.5 to 18.8)11.6 (8.1 to 16.4)
Serotype 16F7.1 (5.9 to 8.5)1.1 (0.9 to 1.3)9.8 (7.8 to 12.4)2.0 (1.5 to 2.7)7.2 (5.5 to 9.6)
Serotype 17F3.7 (3.0 to 4.5)0.9 (0.8 to 1.1)13.5 (9.5 to 19.2)8.1 (5.6 to 11.7)6.5 (4.6 to 9.3)
Serotype 20A3.7 (3.0 to 4.5)0.9 (0.8 to 1.0)12.2 (9.3 to 16.0)6.0 (4.4 to 8.3)4.4 (3.1 to 6.1)
Serotype 23A8.4 (6.2 to 11.6)1.4 (1.0 to 1.9)19.0 (13.5 to 26.9)2.5 (1.3 to 4.9)16.3 (10.3 to 25.7)
Serotype 23B21.4 (16.2 to 28.1)4.2 (2.9 to 6.0)35.5 (25.9 to 48.6)5.2 (3.5 to 7.6)26.1 (17.5 to 38.9)
Serotype 24F25.8 (19.5 to 34.0)1.0 (0.8 to 1.3)31.1 (22.8 to 42.6)0.9 (0.7 to 1.3)39.5 (27.4 to 56.9)
Serotype 3116.7 (12.5 to 22.3)0.9 (0.7 to 1.2)35.6 (24.8 to 51.2)1.7 (1.1 to 2.6)30.5 (19.1 to 48.6)
Serotype 35B6.0 (4.8 to 7.4)1.0 (0.8 to 1.2)7.2 (5.6 to 9.2)1.4 (1.1 to 1.8)5.7 (4.2 to 7.9)
SecondaryPercentage of Participants Who Achieve a ≥4-fold Increase in Serotype-specific OPA Responses

Activity for the serotypes contained in V116 was determined using a MOPA. The percentage of participants with a ≥4-fold rise from baseline to at 30 days post-vaccination for OPA responses with 95% confidence intervals are presented.

Time frame:
Day 1 (Baseline) and 30 days post-vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieve a ≥4-fold Increase in Serotype-specific OPA Responses
Percentage of ParticipantsCohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116
Serotype 354.9 (46.9 to 62.6)54.9 (44.2 to 65.4)64.1 (55.3 to 72.3)66.2 (53.7 to 77.2)48.7 (37.0 to 60.4)
Serotype 6A57.9 (50.1 to 65.4)58.6 (47.6 to 69.1)46.3 (37.7 to 55.1)18.2 (9.8 to 29.6)56.2 (45.3 to 66.7)
Serotype 7F38.5 (31.7 to 45.6)43.1 (33.4 to 53.3)44.5 (36.3 to 53.0)49.3 (37.0 to 61.6)38.0 (28.1 to 48.8)
Serotype 19A28.4 (22.1 to 35.2)34.6 (25.6 to 44.6)33.6 (26.0 to 41.7)38.9 (27.6 to 51.1)30.0 (20.8 to 40.6)
Serotype 22F53.9 (46.6 to 61.1)54.9 (44.7 to 64.8)77.4 (69.0 to 84.4)65.6 (52.7 to 77.1)50.0 (39.5 to 60.5)
Serotype 33F19.8 (14.2 to 26.4)19.4 (11.9 to 28.9)52.0 (42.9 to 61.0)56.0 (41.3 to 70.0)29.4 (20.0 to 40.3)
Serotype 833.3 (26.8 to 40.4)2.8 (0.6 to 7.9)70.2 (62.2 to 77.4)74.6 (62.9 to 84.2)34.4 (25.0 to 44.8)
Serotype 9N22.0 (16.3 to 28.7)6.5 (2.6 to 12.9)57.4 (48.6 to 65.8)67.9 (53.7 to 80.1)39.1 (28.8 to 50.1)
Serotype 10A46.0 (38.9 to 53.2)2.7 (0.6 to 7.7)74.3 (66.5 to 81.1)67.6 (55.5 to 78.2)49.5 (38.9 to 60.0)
Serotype 11A53.8 (46.3 to 61.1)12.1 (6.2 to 20.6)73.3 (64.8 to 80.6)53.8 (41.0 to 66.3)59.0 (47.7 to 69.7)
Serotype 12F62.8 (55.8 to 69.4)6.3 (2.5 to 12.5)93.0 (87.8 to 96.5)81.9 (71.1 to 90.0)60.2 (49.5 to 70.2)
Serotype 15A53.5 (45.0 to 61.9)12.8 (6.3 to 22.3)70.9 (61.5 to 79.2)35.0 (20.6 to 51.7)59.7 (46.4 to 71.9)
Serotype 15C61.4 (54.2 to 68.3)10.2 (5.2 to 17.5)84.4 (77.3 to 90.0)72.1 (59.9 to 82.3)72.0 (60.9 to 81.3)
Serotype 16F68.0 (60.5 to 74.9)8.0 (3.5 to 15.2)70.5 (61.9 to 78.1)30.9 (20.2 to 43.3)70.9 (60.1 to 80.2)
Serotype 17F37.7 (30.7 to 45.2)2.0 (0.2 to 7.0)74.1 (65.2 to 81.8)62.5 (49.5 to 74.3)54.4 (42.8 to 65.7)
Serotype 20A37.5 (30.5 to 44.9)2.9 (0.6 to 8.1)76.7 (68.5 to 83.7)60.9 (48.4 to 72.4)46.9 (35.7 to 58.3)
Serotype 23A59.9 (51.8 to 67.6)21.1 (12.5 to 31.9)73.7 (64.8 to 81.4)34.2 (19.6 to 51.4)80.0 (68.2 to 88.9)
Serotype 23B74.9 (68.1 to 80.9)40.4 (31.1 to 50.2)80.6 (73.5 to 86.5)43.7 (31.9 to 56.0)80.9 (71.4 to 88.2)
Serotype 24F80.2 (73.8 to 85.7)7.7 (3.1 to 15.2)81.9 (74.1 to 88.2)4.9 (1.0 to 13.7)89.0 (80.2 to 94.9)
Serotype 3170.9 (63.7 to 77.5)8.2 (3.6 to 15.6)81.3 (73.7 to 87.5)18.0 (9.4 to 30.0)82.1 (72.3 to 89.6)
Serotype 35B55.2 (47.7 to 62.5)7.5 (3.3 to 14.3)65.3 (56.9 to 73.0)7.0 (2.3 to 15.7)57.6 (46.4 to 68.3)
SecondaryGeometric Mean Fold Rise of Serotype-specific IgG

Activity for the serotypes contained in V116 was determined using a PnECL assay. Geometric mean fold rise (GMFR) is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline. The GMFRs IgG responses from baseline to 30 days post-vaccination with 95% confidence intervals are presented.

Time frame:
Day 1 (Baseline) and 30 days post-vaccination
Reported as:
Geometric mean · Ratio
Geometric Mean Fold Rise of Serotype-specific IgG
RatioCohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116
Serotype 33.6 (3.2 to 4.0)3.1 (2.6 to 3.7)3.7 (3.2 to 4.3)5.7 (4.3 to 7.4)2.9 (2.3 to 3.5)
Serotype 6A5.9 (5.0 to 7.1)8.0 (6.1 to 10.6)3.3 (2.7 to 4.0)2.5 (1.9 to 3.2)4.4 (3.4 to 5.7)
Serotype 7F3.3 (2.8 to 3.8)2.9 (2.3 to 3.5)3.2 (2.7 to 3.8)3.2 (2.6 to 3.9)3.2 (2.6 to 4.0)
Serotype 19A2.3 (2.0 to 2.7)3.4 (2.8 to 4.2)2.2 (1.9 to 2.5)3.0 (2.4 to 3.6)2.0 (1.7 to 2.4)
Serotype 22F4.2 (3.6 to 4.9)3.4 (2.8 to 4.2)14.3 (11.4 to 18.0)8.5 (6.2 to 11.6)3.5 (2.7 to 4.6)
Serotype 33F2.2 (1.9 to 2.5)1.8 (1.5 to 2.1)8.6 (7.1 to 10.5)10.5 (7.9 to 13.9)2.4 (1.9 to 3.0)
Serotype 82.7 (2.4 to 3.1)1.0 (0.9 to 1.1)12.1 (9.8 to 15.0)14.4 (10.3 to 20.0)2.3 (1.9 to 2.8)
Serotype 9N2.9 (2.4 to 3.4)1.4 (1.2 to 1.6)8.7 (7.1 to 10.6)9.1 (6.8 to 12.1)3.2 (2.6 to 3.9)
Serotype 10A4.4 (3.7 to 5.2)1.0 (0.9 to 1.0)18.9 (15.3 to 23.4)10.1 (7.6 to 13.4)4.2 (3.1 to 5.5)
Serotype 11A4.1 (3.6 to 4.7)1.0 (0.9 to 1.0)10.3 (8.5 to 12.6)5.6 (4.4 to 7.2)3.5 (2.7 to 4.3)
Serotype 12F4.2 (3.6 to 5.0)1.0 (0.9 to 1.1)14.2 (11.3 to 17.9)8.4 (5.8 to 12.0)3.5 (2.7 to 4.5)
Serotype 15A12.2 (10.1 to 14.7)1.0 (0.9 to 1.1)24.5 (19.7 to 30.3)2.4 (2.0 to 3.0)16.6 (12.0 to 22.9)
Serotype 15C5.8 (4.9 to 6.9)1.0 (0.9 to 1.2)18.8 (14.9 to 23.8)6.2 (4.8 to 8.2)6.4 (5.0 to 8.1)
Serotype 16F15.2 (12.7 to 18.2)1.1 (1.0 to 1.2)15.7 (12.9 to 19.0)1.6 (1.3 to 1.8)11.9 (9.2 to 15.4)
Serotype 17F4.7 (4.0 to 5.5)1.0 (0.9 to 1.1)17.4 (14.3 to 21.1)10.5 (7.8 to 14.1)3.8 (2.9 to 5.0)
Serotype 20A3.8 (3.3 to 4.4)1.0 (0.9 to 1.1)14.8 (12.2 to 17.9)8.5 (6.4 to 11.4)3.7 (2.9 to 4.8)
Serotype 23A13.5 (11.1 to 16.5)1.8 (1.5 to 2.2)18.9 (15.3 to 23.4)2.3 (1.9 to 2.7)13.1 (9.6 to 17.7)
Serotype 23B8.2 (6.7 to 10.0)2.7 (2.1 to 3.5)7.3 (6.0 to 8.9)2.3 (1.9 to 2.9)7.3 (5.4 to 9.7)
Serotype 24F26.9 (21.8 to 33.1)1.0 (0.9 to 1.1)21.7 (17.3 to 27.2)1.0 (0.9 to 1.1)24.4 (17.1 to 34.9)
Serotype 3113.1 (11.0 to 15.6)1.1 (1.0 to 1.2)14.4 (11.9 to 17.3)1.5 (1.3 to 1.8)13.0 (9.9 to 17.0)
Serotype 35B16.8 (13.9 to 20.3)1.0 (0.9 to 1.0)15.6 (12.9 to 18.7)0.9 (0.9 to 1.0)15.7 (11.9 to 20.8)
SecondaryPercentage of Participants Who Achieve a ≥4-fold Increase in Serotype-specific IgG Response

Activity for the serotypes contained in V116 was determined using a PnECL assay. The percentage of participants with a ≥4-fold rise from baseline to at 30 days post-vaccination for IgG responses with 95% confidence intervals are presented.

Time frame:
Day 1 (Baseline) and 30 days post-vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieve a ≥4-fold Increase in Serotype-specific IgG Response
Percentage of ParticipantsCohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116
Serotype 342.7 (36.1 to 49.6)36.8 (28.0 to 46.2)40.7 (33.2 to 48.6)54.3 (42.9 to 65.4)35.4 (26.0 to 45.6)
Serotype 6A56.2 (49.3 to 62.8)65.0 (55.6 to 73.5)35.9 (28.7 to 43.7)27.2 (17.9 to 38.2)45.5 (35.4 to 55.8)
Serotype 7F34.7 (28.4 to 41.4)29.9 (21.8 to 39.1)37.7 (30.4 to 45.5)33.3 (23.2 to 44.7)37.4 (27.9 to 47.7)
Serotype 19A24.7 (19.1 to 30.9)37.6 (28.8 to 47.0)19.8 (14.0 to 26.6)33.3 (23.2 to 44.7)19.2 (12.0 to 28.3)
Serotype 22F39.3 (32.8 to 46.1)35.0 (26.5 to 44.4)78.4 (71.4 to 84.4)65.4 (54.0 to 75.7)43.4 (33.5 to 53.8)
Serotype 33F19.1 (14.1 to 24.9)12.8 (7.4 to 20.3)72.5 (65.0 to 79.1)75.3 (64.5 to 84.2)27.3 (18.8 to 37.1)
Serotype 829.5 (23.6 to 36.0)0.9 (0.0 to 4.7)78.4 (71.4 to 84.4)76.5 (65.8 to 85.2)26.3 (17.9 to 36.1)
Serotype 9N31.8 (25.7 to 38.4)7.7 (3.6 to 14.1)68.9 (61.2 to 75.8)72.8 (61.8 to 82.1)36.4 (26.9 to 46.6)
Serotype 10A45.5 (38.7 to 52.3)0.9 (0.0 to 4.7)82.6 (76.0 to 88.1)80.2 (69.9 to 88.3)46.5 (36.4 to 56.8)
Serotype 11A43.8 (37.2 to 50.7)0.0 (0.0 to 3.1)72.5 (65.0 to 79.1)63.0 (51.5 to 73.4)43.4 (33.5 to 53.8)
Serotype 12F44.5 (37.9 to 51.4)2.6 (0.5 to 7.3)75.4 (68.2 to 81.8)60.5 (49.0 to 71.2)39.4 (29.7 to 49.7)
Serotype 15A73.6 (67.3 to 79.3)0.9 (0.0 to 4.7)89.8 (84.2 to 94.0)28.4 (18.9 to 39.5)77.8 (68.3 to 85.5)
Serotype 15C57.5 (50.7 to 64.2)3.4 (0.9 to 8.5)80.1 (73.2 to 85.9)64.2 (52.8 to 74.6)66.7 (56.5 to 75.8)
Serotype 16F82.1 (76.4 to 87.0)2.6 (0.5 to 7.3)84.9 (78.6 to 90.0)13.6 (7.0 to 23.0)77.8 (68.3 to 85.5)
Serotype 17F48.9 (42.1 to 55.7)1.7 (0.2 to 6.0)83.8 (77.4 to 89.1)74.1 (63.1 to 83.2)44.4 (34.5 to 54.8)
Serotype 20A36.5 (30.1 to 43.3)0.9 (0.0 to 4.7)83.2 (76.7 to 88.6)69.1 (57.9 to 78.9)49.5 (39.3 to 59.7)
Serotype 23A77.6 (71.5 to 83.0)17.1 (10.8 to 25.2)86.7 (80.6 to 91.5)21.0 (12.7 to 31.5)77.8 (68.3 to 85.5)
Serotype 23B64.8 (58.1 to 71.2)26.5 (18.8 to 35.5)60.5 (52.6 to 67.9)21.0 (12.7 to 31.5)64.6 (54.4 to 74.0)
Serotype 24F85.4 (80.0 to 89.8)0.0 (0.0 to 3.1)88.0 (82.1 to 92.5)0.0 (0.0 to 4.5)83.8 (75.1 to 90.5)
Serotype 3179.7 (73.8 to 84.9)2.6 (0.5 to 7.3)84.4 (78.0 to 89.6)11.1 (5.2 to 20.0)80.8 (71.7 to 88.0)
Serotype 35B83.9 (78.4 to 88.6)0.0 (0.0 to 3.1)82.6 (76.0 to 88.1)0.0 (0.0 to 4.5)84.8 (76.2 to 91.3)

Adverse events

Collected over Up to approximately 30 days post-vaccination for non-serious adverse events (AEs) and up to approximately 180 days for serious AEs and deaths.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: V1160/231 (0%)2/230 (0.9%)107/230 (46.5%)
Cohort 1: PCV150/119 (0%)4/117 (3.4%)66/117 (56.4%)
Cohort 2: V1160/176 (0%)2/174 (1.1%)85/174 (48.9%)
Cohort 2: PPSV230/85 (0%)3/85 (3.5%)52/85 (61.2%)
Cohort 3: V1160/106 (0%)2/105 (1.9%)51/105 (48.6%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventCohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116
CholangitisHepatobiliary disorders0/2300/1170/1741/850/105
Ischaemic strokeNervous system disorders0/2300/1170/1741/850/105
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2300/1171/1741/850/105
CholelithiasisHepatobiliary disorders0/2300/1170/1740/851/105
Urinary tract infectionInfections and infestations0/2300/1170/1740/851/105
Cardiac failureCardiac disorders0/2301/1170/1740/850/105
Myocardial ischaemiaCardiac disorders0/2301/1170/1740/850/105
Aortoenteric fistulaGastrointestinal disorders0/2301/1170/1740/850/105
Mallory-Weiss syndromeGastrointestinal disorders0/2301/1170/1740/850/105
Small intestinal perforationGastrointestinal disorders0/2301/1170/1740/850/105
Most frequent other events
Most frequent other events
EventCohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116
Injection site painGeneral disorders82/23051/11772/17440/8546/105
FatigueGeneral disorders33/23020/11733/17412/8523/105
Injection site swellingGeneral disorders20/23010/1178/17414/8511/105
HeadacheNervous system disorders17/23011/11718/17410/859/105
MyalgiaMusculoskeletal and connective tissue disorders17/2305/11717/1749/859/105
Injection site erythemaGeneral disorders19/2309/11714/1748/858/105

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116Total
Mean68.8 ± 7.569.0 ± 7.165.4 ± 7.865.4 ± 6.671.0 ± 7.667.9 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116Total
Female117601014956383
Male11459753650334
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116Total
Hispanic or Latino2217341614103
Not Hispanic or Latino2071021426992612
Unknown or Not Reported200002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: V116Cohort 1: PCV15Cohort 2: V116Cohort 2: PPSV23Cohort 3: V116Total
American Indian or Alaska Native000000
Asian9647552513236
Native Hawaiian or Other Pacific Islander000000
Black or African American6331619
White127691185986459
More than one race200013
Unknown or Not Reported000000
08

Study locations

51 sites
  • Central Research Associates ( Site 0024)
    Birmingham, Alabama 35205, United States
  • Lenzmeier Family Medicine/CCT Research ( Site 0008)
    Glendale, Arizona 85308, United States
  • Fiel Family and Sports Medicine, PC/CCT Research ( Site 0006)
    Tempe, Arizona 85283, United States
  • Southland Clinical Research Center ( Site 0026)
    Fountain Valley, California 92708, United States
  • Diablo Clinical Research, Inc. ( Site 0019)
    Walnut Creek, California 94598, United States
  • Alliance for Multispecialty Research, LLC ( Site 0020)
    Coral Gables, Florida 33134, United States
  • Indago Research & Health Center, Inc ( Site 0005)
    Hialeah, Florida 33012, United States
  • Advanced Medical Research Institute ( Site 0018)
    Miami, Florida 33174, United States
  • Solaris Clinical Research ( Site 0025)
    Meridian, Idaho 83646, United States
  • Centennial Medical Group ( Site 0002)
    Elkridge, Maryland 21075, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0016)
    Troy, Michigan 48098, United States
  • Meridian Clinical Research, LLC ( Site 0009)
    Norfolk, Nebraska 68701, United States
  • Advanced Medical Research ( Site 0001)
    Maumee, Ohio 43537, United States
  • University of Texas Medical Branch-Sealy Institute for Vaccine Sciences Clinical Trials Program ( Si
    Galveston, Texas 77555, United States
  • Health Research of Hampton Roads, Inc. ( Site 0003)
    Newport News, Virginia 23606, United States
  • Hamilton Medical Research Group ( Site 0114)
    Hamilton, Ontario L8M 1K7, Canada
  • Milestone Research Inc. ( Site 0104)
    London, Ontario N5W 6A2, Canada
  • Manna Research Mirabel ( Site 0109)
    Mirabel, Quebec J7J 2K8, Canada
  • CHU de Québec-Université Laval-Équipe de recherche en vaccination ( Site 0120)
    Quebec City, Quebec G1E 7G9, Canada
  • Diex Recherche Sherbrooke Inc. ( Site 0101)
    Sherbrooke, Quebec J1L 0H8, Canada
  • CHU Bordeaux Haut-Leveque ( Site 0202)
    Pessac, Aquitaine 33600, France
  • CHRU de Brest ( Site 0200)
    Brest, Finistere 29609, France
  • centre hospitalier lyon sud ( Site 0204)
    Pierre-Bénite, Rhone 69310, France
  • Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0203)
    Paris, 75679, France
  • Rambam Health Care Campus ( Site 0303)
    Haifa, 3109601, Israel
  • Maccabi Health Services - Holon ( Site 0305)
    Holon, Israel
  • Maccabi Healthcare Services ( Site 0306)
    Jerusalem, 71713, Israel
  • Hadassah Medical Center-Clinical Reaserch Unit ( Site 0300)
    Jerusalem, 9112001, Israel
  • Meir Medical Center ( Site 0301)
    Kfar Saba, 4428164, Israel
  • Sheba Medical Center-Early Phase Clinical Trials Unit ( Site 0304)
    Ramat Gan, 5265601, Israel
  • Clalit Health Services - Sakhnin Community Clinic-Research Unit ( Site 0302)
    Sakhnin, 3081000, Israel
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 0400)
    Milano, Lombardia 20122, Italy
  • Ospedale San Raffaele ( Site 0403)
    Milano, Lombardia 20132, Italy
  • A.O.U. Policlinico Paolo Giaccone ( Site 0402)
    Palermo, Sicilia 90127, Italy
  • Azienda Ospedaliero Universitaria Policlinico Riuniti di Foggia ( Site 0405)
    Foggia, 71100, Italy
  • PS Clinic ( Site 0700)
    Fukuoka, 812-0025, Japan
  • Nishikumamoto Hospital ( Site 0701)
    Kumamoto, 861-4157, Japan
  • Gachon University Gil Medical Center ( Site 0755)
    Namdong-gu, Incheon 21565, Korea, Republic of
  • Korea University Ansan Hospital ( Site 0751)
    Ansan-si, Kyonggi-do 15355, Korea, Republic of
  • The Catholic University of Korea, Eunpyeong St. Mary's Hospital ( Site 0752)
    Seoul, 03312, Korea, Republic of
  • The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 0753)
    Seoul, 06591, Korea, Republic of
  • Hallym University Kangnam Sacred Heart Hospital-Internal Medicine ( Site 0754)
    Seoul, 07441, Korea, Republic of
  • Korea University Guro Hospital ( Site 0750)
    Seoul, Korea, Republic of
  • HOSPITAL CLÍNIC DE BARCELONA-Medicina Preventiva i Epidemiologia ( Site 0503)
    Barcelona, Cataluna 08036, Spain
  • EBA CENTELLES ( Site 0500)
    Centelles, Cataluna 08500, Spain
  • Hospital Universitari de Bellvitge ( Site 0505)
    L'Hospitalet de Llobregat, Cataluna 08907, Spain
  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-Respiratory ( Site 0508)
    Pozuelo de Alarcon, Madrid 28223, Spain
  • Hospital Internacional Xanit ( Site 0520)
    Benalmadena, Malaga 29630, Spain
  • Hospital La Princesa ( Site 0515)
    Madrid, 28006, Spain
  • National Cheng Kung University Hospital ( Site 0801)
    Tainan, 704, Taiwan
  • National Taiwan University Hospital ( Site 0800)
    Taipei, 100, Taiwan
09

References and documents

Publications

  • Scott P, Haranaka M, Choi JH, Stacey H, Dionne M, Greenberg D, Grijalva CG, Orenstein WA, Fernsler D, Gallagher N, Zeng T, Li J, Platt HL; STRIDE-6 Study Group. A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (STRIDE-6). Clin Infect Dis. 2024 Dec 17;79(6):1366-1374. doi: 10.1093/cid/ciae383. PubMed 39082735 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in May 2023, 10 months.

Results were first posted in May 2024, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2022
First posted
Jun 16, 2022
StartActual
Jul 12, 2022
Primary completionActual
May 16, 2023
CompletionActual
May 16, 2023
Results first posted
May 1, 2024
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05420961
Responsible party
Sponsor
First posted
Jun 16, 2022
Start date
Jul 12, 2022
Primary completion
May 16, 2023
Completion
May 16, 2023
Results posted
May 1, 2024
Last update
Oct 26, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine

Start the discussion